Financial News

Celsion reports positive interim data

Celsion Corp. (Nasdaq: CLSN) reported positive interim data from a Phase 2 DIGNITY Trial of ThermoDox to treat recurrent chest wall breast cancer. The stock price soared 63 cents to $3.29


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback